Clinical Trials | Clinical

First Patients Dosed in New CA125 Antagonist Study in Ovarian Cancer

September 02, 2021

Two international studies of oregovomab in combination with other anticancer therapies for the treatment of previously treated, recurrent ovarian cancer have dose its first patients, and patients are being recruited to receive the drug in a phase 3 study conducted in the United States.